Severe hepatotoxicity of ritonavir, ombitasvir, paritaprevir, and dasabuvir in a kidney transplant recipient

Saudi J Kidney Dis Transpl. 2019 Sep-Oct;30(5):1184-1186. doi: 10.4103/1319-2442.270279.
No abstract available

Publication types

  • Case Reports
  • Letter

MeSH terms

  • 2-Naphthylamine
  • Anilides / adverse effects
  • Anilides / therapeutic use
  • Antiviral Agents / adverse effects*
  • Antiviral Agents / therapeutic use
  • Carbamates / adverse effects
  • Carbamates / therapeutic use
  • Chemical and Drug Induced Liver Injury*
  • Cyclopropanes
  • Cyclosporine / blood
  • Hepatitis C, Chronic / drug therapy
  • Hepatitis C, Chronic / etiology
  • Humans
  • Kidney Transplantation / adverse effects*
  • Lactams, Macrocyclic
  • Macrocyclic Compounds / adverse effects
  • Macrocyclic Compounds / therapeutic use
  • Male
  • Middle Aged
  • Proline / analogs & derivatives
  • Ritonavir / adverse effects
  • Ritonavir / therapeutic use
  • Sulfonamides / adverse effects
  • Sulfonamides / therapeutic use
  • Uracil / adverse effects
  • Uracil / analogs & derivatives
  • Uracil / therapeutic use
  • Valine

Substances

  • Anilides
  • Antiviral Agents
  • Carbamates
  • Cyclopropanes
  • Lactams, Macrocyclic
  • Macrocyclic Compounds
  • Sulfonamides
  • ombitasvir
  • Uracil
  • Cyclosporine
  • Proline
  • 2-Naphthylamine
  • dasabuvir
  • Valine
  • Ritonavir
  • paritaprevir